PRODUCTION OF HUMAN ANTIMALARIAL CRISIS FORM FACTOR

人类抗疟危机因子的生产

• 批准号: 3488419
• 负责人: JEFFREY F WILLIAMS
• 金额: $ 5万
• 依托单位: PROBE-TEK, INC.
• 依托单位国家: 美国
• 财政年份: 1986
• 资助国家: 美国
• 起止时间: 1986-05-01 至 1986-10-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3488419
• 关键词: Plasmodium; Plasmodium falciparum; antimalarial agents; antimicroorganism antibody; antiserum; cellular immunity; high performance liquid chromatography; human tissue; hybridomas; immunologic techniques; immunotherapy; ion exchange chromatography; lymphokines; malaria; malaria vaccines; microorganism immunology; molecular sieving; monoclonal antibody; parasitic disease chemotherapy; protozoal antigen; reversed phase chromatography

Malaria, due to Plasmodium falciparum remains the most important human infectious disease in the world. Past control measures have been inadequate to limit the incidence and consequences of the disease. Currently, a great deal of attention and funding is being directed to the search for an antimalarial vaccine. These programs support the search for parasite antigens which could stimulate protective immunity in humans via antibody-dependent mechanisms. However, the acquired protective immunity to malaria found in humans living in malarious areas is poorly understood. It is possible, if not likely, that vaccines based on antibody alone will be of relatively limited use in controlling malaria. Jensen et al reported strong evidence that naturally acquired immunity to falciparum malaria in Sudan involves a major contribution from cell-mediated immune responses. In vitro, Sudanese immune sera cause a profound retardation in the intraerythrocytic development of P. falciparum resulting in the appearance of morphologically typical "crisis forms." We have termed the factor responsible for the activity crisis-form factor (CFF). The long term objectives of this research are to be able to produce CFF for use as a possible therapeutic agent in the clinical management of malaria, or to stimulate production of protective substance in vivo as a potential means of prophylaxis. Both approaches require the purification, characterization and specific quantitation of CFF from human immune serum sources. The specific aim of the Phase 1 feasibility study is to develop immunoassay procedures based on the production of anti-CFF monoclonal antibodies.

疟疾，由于恶性疟原虫仍然是最重要的人类 世界上的传染病。 过去的控制措施 不足以限制疾病的发生和后果。 目前，大量的注意力和资金正被引导到 寻找抗疟疾疫苗。 这些程序支持搜索 寄生虫抗原可以刺激人类的保护性免疫， 抗体依赖性机制。 然而，获得的保护性免疫力 对生活在疟疾流行地区的人类中发现的疟疾的了解很少。 如果不太可能的话，仅仅基于抗体的疫苗也有可能 在控制疟疾方面的作用相对有限。 詹森等人报道， 强有力的证据表明， 苏丹涉及细胞介导的免疫反应的主要贡献。 在体外，苏丹的免疫血清会引起严重的发育迟缓， 恶性疟原虫的红细胞内发育导致出现 典型的“危机形态”“我们称之为 活动危机形式因子（CFF）。 长期 本研究的目标是能够生产CFF用作 在疟疾的临床管理中可能的治疗剂，或 刺激体内保护性物质产生作为一种潜在手段 预防。 这两种方法都需要纯化、表征 和来自人免疫血清来源的CFF的特异性定量。 的 第1阶段可行性研究的具体目标是开发免疫测定法 基于抗CFF单克隆抗体生产的方法。